Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer

被引：8
|
作者：
Wang, Yan [1 ]
Lin, Rongjie [1 ,2 ]
Ling, Huan [1 ]
Ke, Yuan [1 ]
Zeng, Yangyang [1 ]
Xiong, Yudi [1 ]
Zhou, Qian [1 ]
Zhou, Fuxiang [1 ,3 ]
Zhou, Yunfeng [1 ,3 ]
机构：
[1] Hubei Key Lab Tumor Biol Behav, Wuhan, Hubei, Peoples R China
[2] Fujian Med Univ, Fujian Canc Hosp, Dept Radiat Oncol, Canc Hosp, Fuzhou, Fujian, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Hubei, Peoples R China
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1038/s41392-019-0088-z
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibition in cancer: the cell cycle splicing connection
    Sheppard, Karen E.
    AbuHammad, Shatha
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (06)
  • [22] The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia
    Zhang, Jun
    Zhou, Lanlan
    Zhao, Shuai
    Dicker, David T.
    El-Deiry, Wafik S.
    CELL CYCLE, 2017, 16 (12) : 1193 - 1200
  • [23] Dual targeting of CDK4 and MEK as a combination treatment strategy for metastatic colorectal cancer
    Ziemke, Elizabeth
    Dosch, Joseph
    Shettigar, Amrith
    Wan, Shanshan
    Welling, Theodore
    Hardiman, Karin
    Sebolt-Leopold, Judith
    CANCER RESEARCH, 2014, 74 (19)
  • [24] Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer
    Hanada, Keita
    Kawada, Kenji
    Nishikawa, Gen
    Toda, Kosuke
    Maekawa, Hisatsugu
    Nishikawa, Yasuyo
    Masui, Hideyuki
    Hirata, Wataru
    Okamoto, Michio
    Kiyasu, Yoshiyuki
    Honma, Shusaku
    Ogawa, Ryotaro
    Mizuno, Rei
    Itatani, Yoshiro
    Miyoshi, Hiroyuki
    Sasazuki, Takehiko
    Shirasawa, Senji
    Taketo, M. Mark
    Obama, Kazutaka
    Sakai, Yoshiharu
    CANCER LETTERS, 2021, 522 : 129 - 141
  • [25] Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
    Makiko Kobayashi
    Ikuko Takahashi-Suzuki
    Toshiyasu Shimomura
    Yoshikazu Iwasawa
    Hiroshi Hirai
    Investigational New Drugs, 2011, 29 : 921 - 931
  • [26] Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
    Kobayashi, Makiko
    Takahashi-Suzuki, Ikuko
    Shimomura, Toshiyasu
    Iwasawa, Yoshikazu
    Hirai, Hiroshi
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 921 - 931
  • [27] Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
    Raub, Thomas J.
    Wishart, Graham N.
    Kulanthaivel, Palaniappan
    Staton, Brian A.
    Ajamie, Rose T.
    Sawada, Geri A.
    Gelbert, Lawrence M.
    Shannon, Harlan E.
    Sanchez-Martinez, Concepcion
    De Dios, Alfonso
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (09) : 1360 - 1371
  • [28] KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study
    Xu, Duogang
    Liao, Changkang
    Tan, Jing
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (02): : 850 - 855
  • [29] Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
    Rader, JulieAnn
    Russell, Mike R.
    Hart, Lori S.
    Nakazawa, Michael S.
    Belcastro, Lili T.
    Martinez, Daniel
    Li, Yimei
    Carpenter, Erica L.
    Attiyeh, Edward F.
    Diskin, Sharon J.
    Kim, Sunkyu
    Parasuraman, Sudha
    Caponigro, Giordano
    Schnepp, Robert W.
    Wood, Andrew C.
    Pawel, Bruce
    Cole, Kristina A.
    Maris, John M.
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6173 - 6182
  • [30] Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer
    Araujo, Haniel A.
    Pechuan-Jorge, Ximo
    Zhou, Teng
    Do, Minh Truong
    Hu, Xin
    Alvarez, Frank R. Rojas
    Salvatierra, Maria E.
    Ibarguen, Heladio P.
    Lee, Richard
    Raghulan, Rashi
    Shah, Harshit
    Ayala, Mariela A. Moreno
    Chen, Kevin
    Shifrin, Nataliya Tovbis
    Wu, Shuhong
    Soto, Luisa M. Solis
    Negrao, Marcelo V.
    Gibbons, Don L.
    Hong, David S.
    Roth, Jack A.
    Heymach, John V.
    Zhang, Jianjun
    Jiang, Jingjing
    Singh, Mallika
    Smith, Jacqueline A. M.
    Quintana, Elsa
    Skoulidis, Ferdinandos
    CANCER DISCOVERY, 2024, 14 (11) : 2183 - 2208
12345